GlassScriptPhysician profile
Pouya Dayani
NPI 1336293406
$85,422.47
in general payments reported to CMS, 2019-2025
19 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $14K · 2021: $14K · 2022: $19K · 2023: $1,149 · 2024: $2,833 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,515.25 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $29,867.46 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $13,304.18 | 2020-2023 | Eylea |
| Alimera Sciences, INC. | $11,238.37 | 2019-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $11,000.89 | 2019-2021 | |
| Allergan, INC. | $7,769.34 | 2019-2022 | |
| Genentech, INC. | $5,422.41 | 2019 | |
| Alcon Vision LLC | $5,001.37 | 2019-2025 | Unity, Constellation, Ngenuity |
| Apellis Pharmaceuticals, INC. | $551.38 | 2023-2025 | Syfovre |
| Abbvie INC. | $480.21 | 2022-2025 | Ozurdex |
| Genentech USA, INC. | $409.41 | 2019-2025 | Vabysmo |
| Sandoz INC. | $137.41 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $92.99 | 2021 | |
| Astellas Pharma US INC | $62.79 | 2023-2025 | Izervay |
| Samsara Vision | $34.57 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| Neos Therapeutics, LP | $19.63 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.94 | 2021 | |
| Horizon Therapeutics Plc | $13.12 | 2023 | Tepezza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pouya Dayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.